Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKG0106
- Development stage
- Phase 2
- Lead developer
- Skyline Therapeutics
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravitreal
01
Overview
SKG0106 is an investigational, one-time intravitreally delivered gene therapy for ocular diseases, notably neovascular (wet) age-related macular degeneration (nAMD). It consists of a proprietary recombinant adeno-associated virus (rAAV) vector with a uniquely configured transgene genome encoding an anti-VEGF protein. The therapy is designed to inhibit intraocular neovascularization by delivering the anti-VEGF gene directly to the retina, resulting in durable suppression of abnormal blood vessel growth, reduction of vascular leakage, and mitigation of retinal edema. Preclinical studies have demonstrated potent efficacy and a favorable safety profile. Clinical development is ongoing in both the US and China.
02
Targets
Beyond the preview
Go deeper on SKG0106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKG0106.